Tag: Submission

Jaguar Health Announces Napo Therapeutics’ Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition
May 27, 2022

Jaguar Health Announces Napo Therapeutics’ Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2022 / Jaguar Health (NASDAQ:JAGX) announced today that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on …
Full Article
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults | Small Molecules
October 12, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults | Small Molecules

Merck and Ridgeback announce the filing of an emergency filing with the U.S. FDA for molnupiravir, an investigational oral antiviral drug used to treat mild to moderate COVID-19 in at-risk adults Details Category: Small Molecules Posted on Monday, October 11, 2021 6:43 PM Hits: 210 If approved, molnupiravir could become the first oral antiviral drug to treat COVID-19. be Filings …
Full Article
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 11, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

KENILWORTH, NJ & MIAMI–(GESCHÄFTSDRAHT)–Merck (NYSE: MRK), außerhalb der Vereinigten Staaten und Kanadas als MSD bekannt, und Ridgeback Biotherapeutics gaben heute bekannt, dass Merck bei der US-amerikanischen Food and Drug Administration (FDA) einen Zulassungsantrag für den Notfall (EUA) für Molnupiravir eingereicht hat. ein orales antivirales Prüfarzneimittel zur Behandlung von leichtem bis mittelschwerem COVID-19 bei Erwachsenen, bei denen das Risiko besteht, zu …
Full Article